Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe.
Alzheimer's disease
cognitive assessment
diagnosis
mild cognitive impairment
mild neurocognitive disorders
standard neuropsychological assessment
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
11
03
2021
received:
27
07
2020
accepted:
05
04
2021
pubmed:
14
5
2021
medline:
11
3
2022
entrez:
13
5
2021
Statut:
ppublish
Résumé
Harmonized neuropsychological assessment for neurocognitive disorders, an international priority for valid and reliable diagnostic procedures, has been achieved only in specific countries or research contexts. To harmonize the assessment of mild cognitive impairment in Europe, a workshop (Geneva, May 2018) convened stakeholders, methodologists, academic, and non-academic clinicians and experts from European, US, and Australian harmonization initiatives. With formal presentations and thematic working-groups we defined a standard battery consistent with the U.S. Uniform DataSet, version 3, and homogeneous methodology to obtain consistent normative data across tests and languages. Adaptations consist of including two tests specific to typical Alzheimer's disease and behavioral variant frontotemporal dementia. The methodology for harmonized normative data includes consensus definition of cognitively normal controls, classification of confounding factors (age, sex, and education), and calculation of minimum sample sizes. This expert consensus allows harmonizing the diagnosis of neurocognitive disorders across European countries and possibly beyond.
Identifiants
pubmed: 33984176
doi: 10.1002/alz.12365
pmc: PMC9642857
mid: NIHMS1837314
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
29-42Subventions
Organisme : NIA NIH HHS
ID : P30 AG013854
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG016976
Pays : United States
Organisme : NIA NIH HHS
ID : U24 AG072122
Pays : United States
Investigateurs
Ingo Frommann
(I)
Sandra Roeske
(S)
Steffen Wolfsgruber
(S)
L'ubomira Anderkova
(L)
Felbecker Ansgar
(F)
Andrea Chincarini
(A)
Maria Cotelli
(M)
Eva Ntanasi
(E)
Daniel Damian
(D)
Janine Diehl-Schmid
(J)
Valentina Garibotto
(V)
Angélique Gruters
(A)
Manuela Guerreiro
(M)
Maximilian Haas
(M)
Göran Hagman
(G)
Ilona Hallikainen
(I)
Inga Mehrani
(I)
Tuomo Hanninen
(T)
Oskar Hansson
(O)
Jakub Hort
(J)
Adrian Ivanoiu
(A)
Frank Jessen
(F)
Luka Kulic
(L)
Gabriela Latour
(G)
Alberto Lleó
(A)
Rosa Manenti
(R)
Shima Mehrabian
(S)
Sharon Naismith
(S)
Pierre-Jean Ousset
(PJ)
Hans-Albert Pihan
(HA)
Tideman Pontus
(T)
Geraint Price
(G)
Margarita Raycheva
(M)
Irena Rektorova
(I)
Stefania Rossi
(S)
Isabel Sala Matavera
(IS)
Eric Salmon
(E)
Isabel Santana
(I)
Egemen Savaskan
(E)
Nikolaos Scarmeas
(N)
Ann-Katrin Schild
(AK)
Tanja Richter-Schmidinger
(T)
Hilkka Soininen
(H)
Franziska Stalder
(F)
Katya Stoyanova
(K)
Latchezar Traykov
(L)
Paul Unschuld
(P)
Sergi Valero
(S)
Bruno Vellas
(B)
Asmus Vogel
(A)
Martin Vyhnalek
(M)
Gunhild Waldemar
(G)
Görser Yener
(G)
Deniz Yerlikaya
(D)
Informations de copyright
© 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
APA. Diagnostic and Statistical Manual of Mental Disorders. 5th. 2013.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.
Cerami C, Dubois B, Boccardi M, Monsch AU, Demonet JF, Cappa SF. Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:153-166.
Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol. 2017;16(8):661-676.
Gibbons LE, Carle AC, Mackin RS, et al. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6(4):517-527.
Mukherjee S, Mez J, Trittschuh EH, et al. Genetic data and cognitively defined late-onset Alzheimer's disease subgroups. Mol Psychiatry. 2018.
Weintraub S, Besser L, Dodge HH, et al. Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer disease and associated disorders. 2018;32(1):10-17. https://doi.org/10.1097/wad.0000000000000223
Wang H, Fan Z, Shi C, et al. Consensus statement on the neurocognitive outcomes for early detection of mild cognitive impairment and Alzheimer dementia from the Chinese Neuropsychological Normative (CN-NORM) Project. J Glob Health. 2019;9(2):20320.
Boccardi M, Gallo V, Yasui Y, et al. The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology. Neurobiol Aging. 2017;52:141-152.
Jennen-Steinmetz C, Wellek S. A new approach to sample size calculation for reference interval studies. Stat Med. 2005;24(20):3199-3212.
Shirk SD, Mitchell MB, Shaughnessy LW, et al. A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery. Alzheimer's. Research Therapy. 2011;3(6):32.
Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol. 1987;3(1):13-36.
Dodich A, Cerami C, Cappa SF, et al. Combined Socio-Behavioral Evaluation Improves the Differential Diagnosis Between the Behavioral Variant of Frontotemporal Dementia and Alzheimer's Disease: in Search of Neuropsychological Markers. J Alzheimers Dis. 2018;61(2):761-772.
Buschke H. Cued recall in amnesia. J Clin Neuropsychol. 1984;6(4):433-440.
Rami L, Sole-Padulles C, Fortea J, et al. Applying the new research diagnostic criteria: mRI findings and neuropsychological correlations of prodromal AD. Int J Geriatr Psychiatry. 2012;27(2):127-134.
Derby CA, Burns LC, Wang C, et al. Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. Neurology. 2013;80(14):1307-1314.
Wagner M, Wolf S, Reischies FM, et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology. 2012;78(6):379-386.
Sarazin M, Chauvire V, Gerardin E, et al. The amnestic syndrome of hippocampal type in Alzheimer's disease: an MRI study. J Alzheimers Dis. 2010;22(1):285-294.
Sarazin M, Berr C, Rotrou Jde, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology. 2007;69(19):1859-1867.
Grande G, Vanacore N, Vetrano DL, et al. Free and cued selective reminding test predicts progression to Alzheimer's disease in people with mild cognitive impairment. Neurol Sci. 2018;39(11):1867-1875.
Small BJ, Rosnick CB, Fratiglioni L, Bäckman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging. 2004;19(4):592-600.
Teichmann M, Epelbaum S, Samri D, et al. Free and Cued Selective Reminding Test - accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: a large-scale biomarker-characterized monocenter cohort study (ClinAD). Alzheimers Dement. 2017;13(8):913-923.
Zimmerman ME, Katz MJ, Wang C, et al. Comparison of “Word” vs. “Picture” Version of the Free and Cued Selective Reminding Test (FCSRT) in Older Adults. Alzheimer's & Dementia (Amsterdam, Netherlands). 2015;1(1):94-100.
Delgado C, Munoz-Neira C, Soto A, et al. Comparison of the Psychometric Properties of the “Word” and “Picture” Versions of the Free and Cued Selective Reminding Test in a Spanish-Speaking Cohort of Patients with Mild Alzheimer's Disease and Cognitively Healthy Controls. Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists. 2016;31(2):165-175.
Bertoux M, Funkiewiez A, O'Callaghan C, Dubois B, Hornberger M. Sensitivity and specificity of ventromedial prefrontal cortex tests in behavioral variant frontotemporal dementia. Alzheimers Dement. 2013;9(5 Suppl):S84-94.
Caminiti SP, Canessa N, Cerami C, et al. Affective mentalizing and brain activity at rest in the behavioral variant of frontotemporal dementia. NeuroImage Clinical. 2015;9:484-497.
Strauss E, Sherman E, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. Oxford University Press; 2006.
Wolf EJ, Kelly M, Harrington KM, Clark SL, Miller MW. Sample Size Requirements for Structural Equation Models: an Evaluation of Power, Bias, and Solution Propriety. Educ Psychol Meas. 2013;76(6):913-934.
Muthén LK, Muthén BO. How To Use A Monte Carlo Study To Decide On Sample Size and Determine Power. Structural Equation Modeling: A Multidisciplinary Journal. 2002;9(4):599-620.9(4):599-620.
Myers ND, Ahn S, Jin Y. Sample Size and Power Estimates for a Confirmatory Factor Analytic Model in Exercise and Sport: a Monte Carlo Approach. Res Q Exerc Sport. 2011;82(3):412-423.
Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20(4):210-216.
RE Nieuwenhuis-Mark. The death knoll for the MMSE: has it outlived its purpose?. J Geriatr Psychiatry Neurol. 2010;23(3):151-157.
Beck IR, Gagneux-Zurbriggen A, Berres M, Taylor KI, Monsch AU. Comparison of verbal episodic memory measures: consortium to establish a registry for Alzheimer's disease-Neuropsychological Assessment Battery (CERAD-NAB) versus California Verbal Learning Test (CVLT). Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists. 2012;27(5):510-519.
Sala I, Illán-Gala I, Alcolea D, et al. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. Journal of Alzheimer's disease: JAD. 2017;58(3):909-918.
Buschke H, Mowrey WB, Ramratan WS, et al. Memory Binding Test Distinguishes Amnestic Mild Cognitive Impairment and Dementia from Cognitively Normal Elderly. Arch Clin Neuropsychol. 2017;32(8):1037-1038.
Ritchie K, Ropacki M, Albala B, et al. Recommended cognitive outcomes in preclinical Alzheimer's disease: consensus statement from the European Prevention of Alzheimer's Dementia project. Alzheimers Dement. 2017;13(2):186-195.
Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961-970.
Burnham SC, Coloma PM, Li Q-X, et al. Application of the NIA-AA Research Framework: towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. J Prev Alzheimers Dis. 2019;6(4):248-255.
Lim YY, Snyder PJ, Pietrzak RH, et al. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimers Dement (Amst). 2016;2:19-26.
Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: the PACC5. Alzheimer's & dementia (New York, N Y). 2017;3(4):668-677.
Bahar-Fuchs A, Martyr A, Goh AM, Sabates J, Clare L. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev. 2019;3:CD013069.